ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
27 announcements with these filters
Fischer Medical Ventures has intimated a board meeting on 14 November 2026 to consider unaudited Q2 results. The trading window stays closed until 48 hours after results.
Fischer Medical Ventures appointed Mr. Chan Sing En as Independent Director of SG subsidiary FMV Global Innovations, effective 27 Oct 2026. No financial consideration involved.
Fischer Medical Ventures Ltd filed its quarterly shareholding pattern under Regulation 31. This routine disclosure presents the company's current ownership structure.
Fischer Medical Ventures Ltd has issued a Postal Ballot Notice seeking shareholder approval for creating security on subsidiary assets and promoter share pledges for proposed NCD issuance.
Fischer Medical Ventures' board approved a postal ballot notice for RPT consent and borrowing limits, and appointed a scrutinizer. No material transaction or financial figure was decided at this meeting.
Fischer Medical Ventures Limited conducted its 33rd Annual General Meeting via video conferencing on September 29, 2026, with the requisite quorum present.
Fischer Medical Ventures' subsidiaries declared dividends totaling ₹26.95 Crore. This update provides financial information regarding subsidiary cash flows to the exchange.
The company issued a corrigendum to its FY 2025-26 Annual Report. This update corrects financial highlights, auditor report details, and capital management tables.
Fischer Medical Ventures will invest ₹49.88 Crore into its three material wholly-owned subsidiaries via rights issues to support capital expansion.
Fischer Medical Ventures published a Chairman's Letter outlining its Radiology, Preventive Healthcare and Wellness segments plus Indonesia and Philippines deployments. No new transaction, order or capital event is announced.
Fischer Medical Ventures Limited has submitted its Annual Report for the financial year 2025-2026 as per SEBI regulations. The document is available on the company website.
Fischer Medical Ventures Limited has scheduled its 33rd Annual General Meeting on September 29, 2026, through video conferencing. The company also announced the e-voting and book closure dates.
Fischer Medical Ventures is building an AI-enabled healthcare platform integrating medical imaging, screening, and hospital digitization. Strategy focuses on vertically integrated IP across magnets, coils, and AI diagnostics.
Fischer Medical Ventures (FMV) presentation outlines a vertically integrated AI healthcare ecosystem spanning medical imaging, screening, and hospital digitization through subsidiaries like Time Medical and FlynnCare.
Fischer Medical Ventures Limited has fixed September 22, 2026, as the record date for its upcoming dividend. The 33rd Annual General Meeting is scheduled for September 29, 2026.
Fischer Medical Ventures Limited appointed Mr. David Yeow as an Additional Independent Director for five years. The company also reconstituted its Audit Committee and scheduled its 33rd AGM.
Fischer Medical Ventures' subsidiary, Time Medical International Ventures, launched the CLARION 64/128-Slice AI-Driven CT System, marking a significant advancement in medical imaging technology.
Fischer Medical Ventures Limited's subsidiary, Time Medical Philippines, was awarded a province-wide digital healthcare project in Catanduanes, Philippines. The project deploys integrated Health Kiosks and management systems.
Fischer Medical Ventures allotted 4,54,210 equity shares to FMV Holdings Pte Ltd upon conversion of warrants. The allotment realized Rs. 0.80 Crore in consideration.
Fischer Medical Ventures allotted 2.05 crore equity shares upon conversion of warrants, raising ₹35.99 crore. The conversion involved both promoter and non-promoter entities.
Fischer Medical Ventures Limited announced the resignation of two Independent Directors, Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain, effective August 14, 2026.
Fischer Medical Ventures Ltd reported revenue from operations of ₹81.9 Cr (+250.0% YoY) and net profit of ₹3.8 Cr (-22.4% YoY) for Q1 FY27.
Promoters of Fischer Medical Ventures Limited increased their stake by 0.38% through a preferential allotment following warrant conversion on August 12, 2026.
Fischer Medical Ventures filed its Monitoring Agency Report for the quarter ended June 30, 2026, confirming no deviation in the utilization of preferential issue proceeds.
Fischer Medical Ventures allotted 1.43 crore equity shares upon conversion of warrants. The company received Rs 25.06 crore as consideration for the exercise.
Fischer Medical Ventures allotted 66,31,664 equity shares upon conversion of warrants, raising ₹11.64 Crore from promoters. This conversion increases the company's paid-up equity capital.
Shankar Varadharajan and PACs acquired 23 lakh shares of Fischer Medical Ventures Ltd via warrant conversion. The total holding increased to 63.08%.